Tissue remodelling and regeneration in various pathophysiological conditions (e.g. the processes of development, pregnancy, inflammation, wound healing, tissue regeneration, tumor growth, etc.) require angiogenesis, a dynamically coordinated response to stimuli from the extracellular microenvironment. During angiogenic and angiostatic responses, endothelial cells play a central role in the blood vessel formation and regression. Angiostatic responses, which are evoked by crucial factors such as VEGF and DLL4, have been elucidated. However, it has not been revealed, how endothelial cells process these conflicting signals. The study of VEGFRNotch cross-signalling provided some clues. We discuss here the potential roles of cullin 3-based ubiquitin E3 ligases as key players in the process of various signals in endothelial cell function and angiogenesis. Our recent findings show that they function as units to process conflicting signalling crosstalk, epigenetic regulation of key factors, and functional barrier maintenance. We also expect more divergent roles of cullin 3-based ubiquitin E3 ligases in endothelial cell function and angiogenesis, and for their potential use as therapeutic targets.
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We have made great advances in the discovery of growth factors and growth inhibitors since the nerve growth factor (NGF) and epidermal growth factor (EGF) were discovered by Dr. Rita Levi-Montalcini and Dr. Stanley Cohen; a discovery that awarded them the Nobel Prize in Physiology or Medicine in 1986 (1). The discovery of NGF and EGF has opened the door to not only increase the basic knowledge about how cells communicate with each other within tissues, organs and the body, but also to create the sophisticated approaches in modern medicine. Additionally, we are still increasing our knowledge base regarding basic bioscience and also various clinical issues such as tissue regeneration and engineering, inflammation and cancer development.
The characterization of growth factors and their receptors has been expected to result in the development of new therapeutic agents and improved treatments for various clinical diseases. One of the most beneficial and prominent fields leading to clinical application is 'angiogenesis', which has been pioneered by Dr. Judah Folkman and his colleagues (24) . In angiogenesis research, discovery of an endothelial cell-specific growth factor named vascular endothelial cell growth factor (VEGF) has been a driving force in the elucidation of the complete molecular mechanism of endothelial cell homeostasis and angiogenesis (5, 6) .
Angiogenesis is dynamically regulated throughout our lifetime and maintained by a 'tug-of-war' balance of proliferative and cytostatic signals for endothelial cells (ECs) in vivo (7, 8) . Recently, we revealed the molecular mechanism involved in the direct interaction of VEGFR and Notch signals, which are major proliferative and cytostatic signals for ECs, respectively (9) . This study elucidated the significant impact of a cullin3 (CUL3)-based protein ubiquitination system on the EC function. Indeed, we observed that CUL3 knockdown, both in vivo and in vitro, completely destroyed the architecture of blood vessels (see the following section).
In this article, we will review the multiple features of the CUL3 system as a functional master key in ECs, focusing on our recent data.
Overview of CUL3-Based Ubiquitin E3 Ligase and its Regulation
CullinRING E3 ubiquitin ligases (CRLs) are multicomplexes built on a scaffold protein cullin (CUL) as illustrated in Fig. 1 . In human, eight members of the CUL family, CUL1, CUL2, CUL3, CUL4A, CUL4B, CUL5, CUL7 and PARC/CUL9, have been identified and proven to function as the central CRL scaffold (10, 11) . At the catalytic core, the CUL N-termini bind to distinct sets of substrate-receptors (SRs) to recruit different target substrates in each type of CUL and the Ctermini bind a RING finger protein, RBX1 or RBX2, in common which serves as the binding site of the E2 enzyme to mediate the ubiquitin transfer. The activity of CRLs is regulated by common signalling pathways through an interplay between regulatory proteins such as neural precursor cell expressed, developmentally down-regulated 8 (NEDD8) and cullin-associated NEDD8-dissociated protein 1 (CAND1). NEDD8 is an ubiquitin-like protein with 58% identity in their amino acid sequences that is enzymatically conjugated to a specific conserved lysine residue at the CUL C-terminal region, a process termed NEDDylation. This pathway uses, in a stepwise manner, its own set of E1 (NEDD8-activating enzyme; NAE), E2 (UBC12 or UBE2F) and E3 (Rbx1 or Rbx2 and DCN1) enzymes, in a process quite similar to ubiquitination (1214). CRLs are reversibly modified by NEDD8, and deNEDDylation is conducted by a COP9 signalosome (CSN) complex consisting of 8 subunits (15) . The subunit CSN5, a zinc metalloprotease, catalyzes the cleavage of the isopeptide-bond between NEDD8 and CULs. NEDDylation/deNEDDylation cycles of CRLs are thought to be functionally critical for progression through the CRL activation cycle (16) , the allosteric tuning of polyubiquitin chain length and topology (17) , and the dissociation of polyubiquitinated substrates from the CRL complex (18) . Recently, the NAE inhibitor, MLN4924, and the CSN5 inhibitor, CSN5i-3, have been reported to control CRL activity, resulting in the inhibition of tumor growth; this suggests that NEDDylation of CULs could be a therapeutic approach event to protect or activate CRL activity. These small molecules can regulate the protein NEDDylation/ deNEDDylation pathway and MLN4924 is now in clinical trials for cancer therapy (1924) .
Another regulator of CULs is CAND1, an 136 kDa regulatory protein that exclusively and reversibly interact with unNEDDylated CULs (15, 25) . CAND1 binding to CULs competes with the CUL adaptor subunits and therefore modulates the CRL assembly (2628). CAND1 also inhibits NEDDylation by restricting the access of NEDD8 to CULs (29) . Conversely, NEDDylated CRLs do not recruit CAND1. Because CSN promotes deNEDDylation of NEDD8-CULs, it could induce CAND1 recruitment to CRLs and, consequently, facilitate the exchange of SR subunits (30, 31).
It has been well documented that CAND1 exchanges substrate recognition subunits of CUL1 (31) as well as CUL3 (30) based CRLs. However, CAND1's roles in other CRLs have not been convincingly shown yet. Generalization of the CAND1's role in facilitating the exchange of SR subunits requires further studies.
On the other hand, substrate specificities of CRLs are determined by the SRs of each CRL. The SRs show quite different variations in each CRL, although the common activation/inactivation cycle of CRLs is regulated by NEDDylation/deNEDDylation. Among them, the SRs for CUL3-based E3 are single proteins that contain a bric-a-brac, tramtrack, broad complex (BTB) domain that interacts with the N-terminus of CUL3 and an additional protein-interaction domain that selects substrates. [The SR modules for other CULs consist of more than two subunits. Refer to review articles (1, 2)]. The BTB domain is a versatile protein-protein interaction motif that participates in a wide range of cellular functions. One hundred and eighty three BTB domain-containing proteins (BTBPs) have been elucidated in human based on a survey of the protein architecture, genomic distribution and sequence conservation of BTB domain-containing proteins (32) . BTBPs also show other distinct domain structures within their molecules such as Zn finger domain, MATH domain, BACK domain, Kelch domain, Rho domain and ion channel domain. These domains can also interact with their specific partners that are functionally involved in transcriptional regulation, cytoskeleton dynamics, and ion channel assembly and gating. However, the most of them are still uncharacterized and whether they could function as SRs of CUL3-based CRLs to target proteins for ubiquitination is still unknown.
Recently, functionally modulating ubiquitination by CUL3-based CRLs has been reported in addition to leading to the protein degradation by poly-ubiquitination such as CUL3-keap1-Nrf2 (33) axis. For examples, mono-ubiquitination of SEC31 by CUL3-KLHL12 determines the size of COPII vesicles (34), mono-ubiquitination of NOLC1 and TCOF1 by CUL3-KBTBD8 remodels the translational program of differentiating cells in favour to neural crest specification (35) , and mono-ubiquitination of aurora B (36) and EB1(37) by CUL3-KLHL21 regulate cytokinesis and cell migration, respectively. Further, K33-linked poly-ubiquitination of coronin 7 by CUL3-KLHL20 regulates protein trafficking (38) . These intriguing findings urge us to study further CUL3-BTBP systems which would be involved in unique functional modulation.
On the other hand, it has been demonstrated elegantly that some of CRLs, including mainly CUL3 CRLs, requires collaboration with a distinct type of ubiquitin ligase, RING1-IBR-RING2 (RBR), in order to modify target substrates with ubiquitin (39, 40) . These findings substantially indicate the existence of a hierarchy of the CRLs and provide us an insight into the substrate hunting process.
Thus, CRLs have multiple and strictly regulated steps to control their activities, which might suggest that they could contribute to various intracellular events.
Study of VEGFR versus Notch CrossSignalling Revealed a Crucial Implication of CUL3-Based CRLs in Angiogenesis
Whenever once pathophysiological events such as wounding, inflammation and cancer invasion would occur, ECs in pre-existing ECs in blood and lymphatic vessels are able to respond to environmental changes. For example, ECs normally exist in a monolayer tightly connected to each other and form a junctional barrier that is properly maintained to transport of leukocytes and plasma components from the circulation to the tissues and vice versa. Loss of endothelial barrier integrity is a hallmark of chronic inflammatory diseases and leads to edema, tissue damage, and loss of organ function (4143). Furthermore, ECs also respond to a hypoxic environment and migrate to supplying oxygen and nutrients, a process defined as angiogenesis. ECs can be found in a steady-state in pre-existing vessels, this steady-state is maintained by a balance between pro-angiogenic and anti-angiogenic stimuli (44, 45) ; however, how this balance is maintained in ECs is still unknown (Fig. 2) .
VEGF is one of the most characterized and prominent growth factors in ECs because it induces both vessel permeability and angiogenesis through the functional modulation of ECs (46, 47) . On the other hand, the Notch signalling pathway is also well-known to play a key role in angiostatic responses in ECs (4850). In addition to expressing the VEGF receptor (VEGFR), ECs themselves express both Delta-like 4 (DLL4) and Notch. VEGFR and Notch signals are representative signals in angiogenic and angiostatic states, respectively, and there seems to be crosstalk between both signalling pathways. Therefore, we aimed to determine how the both signals were processed and how they contribute to the 'tug-of-war' balance between angiogenic and angiostatic states in vascular homeostasis (8, 9) . In a proangiogenic state, the VEGF-VEGFR signalling pathway somehow alters this balance to become dominant; however, we do not have any piece of evidence to support this statement. To this end, we screened for molecules, induced by VEGF stimulation, that had an impact on Notch signalling. These efforts identified one interesting molecule, the B-cell chronic lymphocytic leukemia/lymphoima 6 (Bcl6)associated zinc finger protein (BAZF) (9) . BAZF is a C2H2-type ZnF protein with a BTB/ POZ domain at the N-terminal, which was originally identified as a transcriptional repressor and highly homologous to Bcl6 (51) . Indeed, BAZF repressed the gene expressions induced by STAT6 to some extent (52) .
Further intensive study of BAZF in VEGFR-Notch cross-signalling also revealed that it also served as an SR of CUL3-based CRLs through its BTB domain rather than as a transcriptional repressor. Bazf expression increased 23-folds after VEGF stimulation in ECs, resulting in an increase in protein expression. Produced BAZF bound to the Notch signalling NEDD8 precursor is processed at the C-terminal by DEN1 and then conjugated to the CRLs through an E1 (NAE), E2 (UBC12 or UBE2M) and E3 (RBX1/2 and DCN1). DeNEDDylation is achieved by the CSN. The small molecule, MLN4924, inhibits NAE, blocking the cascade. NEDD8-CRLs can recruit essential components such as SR and Rbx to form a CRL complex. Another ubiquitin ligase, RING1-IBR-RING2 (RBR) ubiquitin ligase (ARIH), mediates the first ubiquitin transfer from the ubiquitin-conjugating (E2) enzyme to the target substrate on some NEDD8-CRLs, followed by the dissociation of ARIH from the complex. Subsequent ubiquitin transfer is processed by the UBE2R, resulting in ubiquitin chain elongation. The dissociation of polyubiquitinated substrates from the CRL complex may be mediated by deNEDDylation in the CSN. This event may also promote CAND1 recruitment to CRLs and, consequently, facilitate the exchange of SR.
Divergent roles of CUL3 system in angiogenesis factor C promoter binding factor 1 (CBF1) through its ZnF domain at the C-terminal, and recruited CUL3 to its N-terminal. CUL3-CBF-1 linkage through BAZF promoted poly-ubiquitination of CBF1 in a CBF1-BAZF-CUL3 E3 ligase complex, followed by degradation through a proteasome. This mechanism acts as a molecular switch to maintain the angiogenic/antiangiogenic balance (9) .
Bazf knockout in mice (bazf -/-) showed a decrease in endothelial tip cell formation and filopodia protrusion, in addition to a markedly abrogated vascular plexus formation in the retina. This phenotype was superimposed to the retinal phenotype seen in response to Notch activation. Furthermore, skin-wound healing in bazf -/-mice was largely delayed due to the impaired angiogenesis and capillary remodelling. Based on these observations, we proposed that the CUL3-BAZFbased CRL supports angiogenic sprouting via CBF1 poly-ubiquitination and downregulation of Notch signalling (9) . These studies prompted us to look more deeply into whether CUL3 and BAZF could equally contribute to EC function and angiogenesis. Then, we compared the EC phenotypes under CUL3 and BAZF knockdown, both in vitro and in vivo. (Fig. 2) 
CUL3 Knockdown Severely Affects Angiogenesis
Cul3 knockout is lethal to embryonic mice (53) . Moreover, a genome-wide gene knockout screening in human cultured cells indicated the significance of CUL3 for cell viability (54) , suggesting the crucial roles of CUL3 even in ECs maintenance. However, there is no direct evidence describing the role of CUL3 in the regulation of ECs and angiogenesis. Therefore, we therefore estimated the effects of CUL3 knockdown using small interfering RNA (siRNA) on cultured and mouse retinal ECs, which resulted in a loss of vascular architecture more severe than that observed for the bazf knockout phenotype (Fig. 3 : the data in mouse retinal models). These data suggest that CUL3 regulates a much wider range of function in EC using various BTBPs as SRs in addition to the CUL3-BAZF-CBF1 axis. Our findings are supported by a previous study showing that MLN4924, an inhibitor of NEDDylation, suppressed angiogenesis in vivo (55) .
CUL3 is a platform protein for assembly of multisubunit components for ubiquitination of the target substrates and is able to select a partner from 183 BTBP candidates that served as SRs (described above). These fundamental findings strongly indicate the multiple and essential roles of CUL3-based CRLs in the maintenance of ECs homeostasis, prompting us to analyse in detail which of BTBPs and substrates contribute to specific events in angiogenesis.
Impact of CUL3-Based CRLs on the Epigenome of VEGFR Gene Expression
CUL3 knockdown showed an impact on the EC response to VEGF, prompting us to study the VEGFR2 expression in ECs before and after CUL3 knockdown. Human umbilical vein endothelial cells (HUVECs) treated with CUL3 siRNA drastically lost their response to VEGF because of the significant decrease in VEGFR2 mRNA expression. We then investigated the BTB protein responsible for CUL3-mediated VEGFR mRNA regulation by using an siRNA library designed for genes encoding BTB proteins expressed in ECs. Interestingly, we identified the speckle-type POZ protein (SPOP) as a potential candidate. SPOP knockdown also lost the response of ECs to VEGF because of the down regulation of VEGFR mRNA and subsequent decrease in protein production, which was the same observed for the CUL3-knockdown-induced phenotypes (56) . This finding urged us to determine the target substrate of the CUL3-SPOP-based CRL.
SPOP is a relatively well-characterized SR for CUL3 CRLs (57) . Among more than ten reported substrates, we screened a substrate candidate that could respond to VEGFR2 mRNA expression; as a result, we identified the death-domain associated protein (DAXX). DAXX protein levels were elevated under either CUL3 or SPOP knockdown in HUVECs. Additionally, knockdown of DAXX rescued the VEGFR mRNA reduction by either CUL3 or SPOP knockdown. Moreover, HUVECs, in a steady-state condition, showed low DAXX protein level. Overexpression of DAXX cDNA in HUVECs resulted in a remarkable reduction of VEGFR2 mRNA. We also showed that expression of DAXX is inversely correlated with the level of VEGFR2 expression. Furthermore, single knockdown of SPOP and DAXX showed the completely reversed downregulation of VEGFR2 levels (58) . These data suggest that the CUL3-SPOP-DAXX axis plays a crucial role for in VEGFR2 mRNA expression. These findings, however, left further fundamental questions unanswered. Specifically, how does DAXX regulate VEGFR2 mRNA expression and how specific is this regulation? To answer these questions, we performed gene expression profiling before and after knockdown of CUL3, which resulted in the upregulation of Notch1, DLL4 and neuropilin1 (NRP1) genes, as well as VEGFR2, but not VEGFR1. Either of knockdown of SPOP or overexpression of DAXX resulted in the upregulation of these factors; knockdown of CUL3 had the same effect (56) .
These factors are well characterized and crucial angiogenic regulators, suggesting that DAXX could be involved in a wide-range regulation of gene expression, and possibly act as an epigenetic factor for angiogenesis. Indeed, DAXX actively exchanges the conventional histone H3.1 for the histone variant 3.3 in order to inactivate the chromatin loci of the above factors in replication-independent manner (5862). DAXX cooperates with alpha thalassemia/mental retardation syndrome X-linked (ATRX) and possibly other factors to incorporate the histone 3.3 into the heterochromatin loci. It is very interesting and important to determine the fluctuation of the incorporation of histone 3.3 into the gene loci encoding angiogenic regulators such as VEGFR2, Notch1, DLL4 and NRP1 with and without CUL3 or SPOP.
Taken together, these findings suggest that the CUL3-SPOP-DAXX axis plays a very important role in EC function by targeting key angiogenic regulators.
Impact of CUL3-Based CRLs on VE-Cad Regulation and EC Barrier Formation
CUL3 knockdown in cultured ECs and mouse retinal ECs results in disruption of cell-cell contact, suggesting that the CUL3-BTBP axis could play key roles in the structural formation of the EC barrier. Proper maintenance of this barrier is crucial for the transport of leukocytes and plasma components from the circulation to the tissues and vice versa. The disruption of the endothelial barrier allows tumor cells to invade into blood vessels from the primary lesion, resulting in metastasis. The loss of endothelial barrier integrity is the hallmark of chronic inflammatory diseases leading to edema and tissue damage. Sealing of the vessel wall between adjacent ECs is facilitated by homophilic and heterophilic interactions between junctionallyexpressed transmembrane proteins existing in the tight junctions, adherence junctions and others. Among them, vascular endothelial-cadherin (VE-cadherin) is a major adhesion molecule that forms adherent junctions (6368). Genetically engineered mice expressing a VE-cadherin-a-catenin fusion complex (replacing endogenous VE-cadherin) exhibited the stabilized endothelial junctions and the reduced the extravasation of neutrophils and lymphocytes in several models of inflammation, thus providing strong evidence that VE-cadherin plays a crucial role in endothelial barrier integrity (69) . Consequently, we investigated if the CUL3 system could be actively involved in EC barrier formation through the regulation of VE-cadherin.
First, we investigated the effect of MLN4924 on cellcell adhesion and VE-cadherin distribution in cultured Fig. 2 (A) Scheme of the 'tug-of-war' signalling balance between angiogenic and angiostatic states represented by VEGF-VEGFR2 and DLL4-Notch signalling, respectively. ECs constitutively express VEGFR2, Notch and DLL4, and it is considered that there is cross-signalling at some point in the cascades. The process of activation of both the signalling pathways and their function in the maintenance of balance between angiogenic and angiostatic states is yet unknown; however, it is speculated that specific molecules are able to facilitate the cross-signalling (presented as '?' in the figure) that would be able to process the cross-signalling. (B) Scheme depicting the process of cross signalling between VEGF-VEGFR2 and DLL4-Notch signalling pathways. BAZF is upregulated by VEGFR2 activation. The induced BAZF serves as an SR of CUL3-CRL and targets CBF1, which is a crucial transcriptional factor that collaborates with the Notch intracellular domain (NICD) and others molecules in the Notch signal pathway. CUL3-BAZF-based CRL promotes CBF1 poly-ubiquitination and degradation in the proteasome. This CUL3-BAZF-CBF1 axis acts as a molecular switch to maintain the angiogenic/antiangiogenic balance in ECs. (right panels) C57BL/6 mice at post-delivery day 5 (P5). Two days later, retina cups were resected and fixed with 4% paraformaldehyde, followed by staining with isolectin B4Alexa Flour 647. Vascular images were taken by a confocal microscope (Nikon A1).
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HUVECs. Treatment of HUVECs with MLN4924 for 72 h lead to a depletion of VE-cadherin immunostaining at the cell-cell border and a disruption of cell-cell contact. MLN4924 is am NAE inhibitor that has a broad effect on NEDD8-activating proteins including mainly the CUL family. When HUVECs were treated with siRNA directed against a series of CUL family members (CUL1, CUL2, CUL3, CUL4A and CUL5) that are dominantly expressed in HUVECs, CUL3 siRNA, but not others, mimicked the phenotypes described above, suggesting that CUL3 specifically and actively regulated VE-cadherin function and cellcell junction. In addition, cycloheximide treatment after depletion of CUL3 by siRNA revealed that the half-life of the VE-cadherin protein was dramatically reduced. Incidentally, there were no significant differences in VE-cadherin mRNA levels between the treatment and control groups. CUL3 knockdown, as well as MLN4924 treatment, gave rise to high vascular permeability due to the downregulation of the VE-cadherin protein and the subsequent impairment of cellcell contact. Taken together, we concluded that NEDD8-conjugated CUL3 is required for VE-cadherin-mediated endothelial barrier functions (70) . However, the molecular mechanism underlying these observation is yet to be discovered. We speculate that some of the CUL3-BTBP based ubiquitin ligases could target one or more of the destabilizing factor(s) of VEcadherin by poly-ubiquitination and subsequent degradation or functional regulation switching activation and inactivation by other type of ubiquitination. The responsible factor(s) may have been poly-ubiquitinated and degraded in the proteasome, because proteasome inhibitors such as MG132 and epoxomicin showed the dramatically impaired production of VE-cadherin in HUVECs. VEGF is also well known as a vascular permeability factor as well as an angiogenic factor, and regulates VE-cadherin-mediated endothelial barrier functions. VEGF stimulation of endothelial cells induces VE-cadherin internalization within a half hour, and the internalized VE-cadherin is recycled back to the cell surface for re-organization of cell-to-cell adhesion (7174). We speculate that the CUL3-mediated VE-cadherin protein stabilization would be involved in this recycling stage and play a crucial role for the re-organization of cell-to-cell adhesion after VEGF stimulation. Then, we speculate that CUL3-BAZF-CBF1 axis described above and the CUL3-BTBP-subsrate axis, which has not yet been identified, of VE-cadherin regulation might collaborate together in the angiogenic process.
However, it has not yet been reported whether VEcadherin post-translational modification could lead to its degradation. Therefore, it would be intriguing to first determine whether post-translational modifications would be required to accelerate VE-cadherin turn over, and if so, what type of modifications and which type of factors could be involved. In order to determine this, it is definitely necessary to identify the BTBP(s) responsible for the CUL3 knockdowninduced VE-cadherin phenotype. Phenotypic screening by using a BTBPs siRNA library has already revealed promising candidates to us. These promising BTBP candidates could be greatly benefit the identification of real substrates and clarification of the entire molecular mechanism of CUL3-mediated VE-cadherin protein turnover.
Estimation of the CUL3-BTBP Axes in ECs
Target substrates of CUL3-BTBP E3 ligases are still largely unknown because the identification of substrates is not a straightforward process. Because BTBPs are central players for recruiting substrates in CUL3-based CRLs, it is essential to determine the quantity of BTBPs expressed in ECs and, of these, which could serve as real substrate receptors. From this standpoint, we collected BTBP gene expression profiling information from a public database (http:// www.lsbm.org/site_e/database/). This database revealed more than 60 members that are detected at mRNA levels with different expression profiles in ECs derived from tissues such as umbilical vein, retina, skin and lung (Sakaue et al., unpublished observation). Further, in order to estimate how many BTBPs among the more than 60 members expressed in ECs could interact with CUL3, we established an in vitro CUL3-BTBP interaction assay system using an AlphaScreen assay (Sakaue et al., unpublished observation) based on a wheat germ in vitro protein synthesis technique (75) . The established AlphaScreen assay combined with Flag-tagged CUL3 and biotinylated BTBPs revealed at least 40 BTBPs that could interact with CUL3 in vitro, most of which have not been yet characterized (Sakaue et al., unpublished observation).
Conclusion and Perspectives
The CUL3-based CRLs could be involved in a wide range of intracellular events and regulation mechanisms including receptor cross-signalling, epigenetic regulation of gene expression, and cell-cell junctional formation; all of which are described in this review (Fig. 4) . Therefore, identification of each CUL3-BTBP-substrate axis and characterization of its pathophysiological role in ECs might lead to the discovery of novel and highly potent therapeutic targets for angiogenesis. An approach to develop novel angiogenic drugs is to identify compounds that inhibit the formation of the CUL3-BTBP-substrate complex. Inhibitors of BTBP-substrate interactions will be promising drugs expected to have higher specificity and fewer side effects, in comparison to the compounds that inhibit CUL3 activation by NEEDylation or the CUL3-BTBP interaction. Therefore, identification of real substrates for each CUL3-BTBP is definitely important.
